Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs

Abstract

Introduction

Few published reports have described the impact of adherence with biologic agents on hospitalizations and inpatient costs in Crohn’s disease (CD).

Methods

A retrospective claims analysis using the IMS LifeLink Health Plan Claims Database between September 1, 2004 and June 30, 2009 was conducted. Continuous enrollment for 12 months before and 12 months after the index date was required. Patients were required to have ≥2 claims with an International Classification of Diseases, 9th Edition, Clinical Modification diagnosis code for CD (555.xx) preindex, be ≥18 years of age at index, and have ≥4 infliximab infusions with a gap no greater than 12 weeks between each infusion. Patients with 7–9 infliximab infusions (12 months postindex) were considered adherent; patients with 4–6 infliximab infusions were considered nonadherent.

Results

In total, 638 patients were included in the analyses (mean age, 43 years; 58% female in the adherent group and 53% in the nonadherent group). The number of patients who met the definition of adherence was 466 (73%). A smaller proportion of adherent patients had a CD-related emergency room visit, compared with nonadherent patients (11% vs. 17%, P=0.029). A smaller proportion of adherent patients required CD-related hospitalization, compared with nonadherent patients (8% vs. 12%, P=0.117). Among those hospitalized, adherent patients had fewer mean [median] days in the hospital (5.9 [5] days), compared with nonadherent patients (12.8 [8] days, P=0.015). Mean [median] hospital costs were significantly lower for adherent patients ($13,427 [$9,352]), compared with nonadherent patients ($37,783 [$28,864], P=0.001). Multivariate analyses confirmed lower inpatient (P<0.001) costs for adherent versus nonadherent patients.

Conclusion

Adherence with infliximab therapy during the first year of treatment in patients with CD was associated with a shorter hospital length of stay and lower inpatient costs compared with nonadherent patients. Strategies for increasing adherence rates to infliximab maintenance therapy may be valuable in reducing hospitalizations and inpatient costs in patients with CD.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Loftus EV Jr., Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51–60.

    PubMed  Article  Google Scholar 

  2. 2.

    Kappelman MD, Rifas-Shiman SL, Porter C, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in United States children and adults. Gastroenterology. 2008;135:1907–1913.

    PubMed  Article  Google Scholar 

  3. 3.

    Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24:319–328.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn’s disease. Am J Gastroenterol. 2000;95:524–530.

    PubMed  Article  CAS  Google Scholar 

  5. 5.

    Blomqvist P, Ekbom A. Inflammatory bowel disease: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997;32:1134–1139.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastreoenterol. 2000;95:677–683.

    Article  CAS  Google Scholar 

  7. 7.

    Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. 2007;13:1529–1535.

    PubMed  Article  Google Scholar 

  8. 8.

    Bassi A, Dodd S, Williamson P, Bodger K. Cost-ofillness of inflammatory bowel disease in the United Kingdom: a single centre retrospective study. Gut. 2004;53:1471–1478.

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Prescribing Information. REMICADE (infliximab). Malvern, PA: Centocor Ortho Biotech, Inc.; November 2009.

    Google Scholar 

  10. 10.

    Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337:1029–1035.

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomized trial. Lancet. 2002:359:1541–1549.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885.

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340:1398–1405.

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593–1610.

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Colombel JF, Rutgeerts P, Yan S, et al. Infliximab (Remicade) maintenance treatment results in lower hospitalization rate in Crohn’s disease patients. Gastroenterology. 2002;122(Suppl. 4):W1344.

    Google Scholar 

  16. 16.

    Williams JB, Cross RK, Thameen D, et al. Longterm infliximab maintenance infusion regimens and rates of hospitalization, surgery and disability in Crohn’s disease patients. Gastroenterology. 2005;128(Suppl. 2):AW1076.

    Google Scholar 

  17. 17.

    Williams JB, Weber LR, Beaulieu DB, et al. Longterm infliximab maintenance infusion regimens and rates of hospitalization, surgery, and disability in Crohn’s disease. Gastroenterology. 2006;130(Suppl. 2):A–143.

    Google Scholar 

  18. 18.

    Schnitzler F, Fidder H, Ferrante M, et al. Longterm outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a singlecentre cohort. Gut. 2009;58:492–500.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Stein DJ, Ananthakrishnan AN, Issa M, et al. Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn’s disease. Inflamm Bowel Dis. 2010;16:1173–1179.

    PubMed  Google Scholar 

  20. 20.

    Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128:862–869.

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol. 2002;35:151–156.

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn’s disease. Aliment Pharmacol Ther. 2007;26:217–225.

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Mantzaris GJ, Roussos A, Kalantzis C, Koilakou S, Raptis N, Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn’s disease in longterm remission? Inflamm Bowel Dis. 2007;13:446–450.

    PubMed  Article  Google Scholar 

  24. 24.

    Shaya FT, El Khoury AC, Wong W, et al. Persistence with pharmacotherapy for gastrointestinal disease: associated costs of health care. P T. 2006;31:657–665.

    Google Scholar 

  25. 25.

    Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of nonadherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29:247–257.

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020–1024.

    PubMed  Article  Google Scholar 

  27. 27.

    Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2006;24:1099–1103.

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Ther. 2009;26:1–11.

    Article  Google Scholar 

  29. 29.

    PharMetrics, Inc. LifeLink Health Plan Claims Database. Watertown, MA: IMS Health; 2010.

    Google Scholar 

  30. 30.

    Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol. 2000;95:1955–1960.

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47.

    PubMed  Article  Google Scholar 

  32. 32.

    Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105:525–539.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Chureen T. Carter.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Carter, C.T., Waters, H.C. & Smith, D.B. Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs. Adv Therapy 28, 671 (2011). https://doi.org/10.1007/s12325-011-0048-7

Download citation

Keywords

  • Crohn’s disease
  • hospital costs
  • hospitalization
  • infliximab
  • length of stay
  • medication adherence